Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Rezvani, Katayoun  [Clear All Filters]
2021
Mehta RS, Bassett R, Chen J, Valdez BC, Kawedia J, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, et al. Myeloablative Fractionated Busulfan with Fludarabine in Older Patients: Long Term Disease-Specific Outcomes of a Prospective Phase II Clinical Trial. Transplant Cell Ther. 2021.
Wang XShelley, Srour SA, Whisenant M, Subbiah I, Chen THsuan, Ponce D, Gonzalez AGarcia, Kamal M, Mendoza T, Cleeland C, et al. Patient-reported symptom and functioning status during the first 12 months after CAR T-cell therapy for hematological malignancies. Transplant Cell Ther. 2021.
Olson A, Lin R, Marin D, Rafei H, Bdaiwi MH, Thall PF, Basar R, Abudayyeh A, Banerjee P, Aung FM, et al. Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation. J Clin Oncol. 2021:JCO2002608.
2020
Laskowski T, Rezvani K. Adoptive cell therapy: Living drugs against cancer. J Exp Med. 2020;217(12).
Greenbaum U, Kebriaei P, Srour SA, Olson A, Bashir Q, Neelapu SS, Rezvani K, Shpall EJ. Chimeric Antigen Receptor T-cell Therapy Toxicities. Br J Clin Pharmacol. 2020.
Greenbaum U, Yalniz FF, Srour SA, Rezvani K, Singh H, Olson A, Blumenschein G, Hong DS, Shpall EJ, Kebriaei P. Chimeric Antigen Receptor Therapy: How Are We Driving in Solid Tumors?. Biol Blood Marrow Transplant. 2020.
Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, Kerbauy LNassif, Overman B, Thall P, Kaplan M, et al. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. N Engl J Med. 2020;382(6):545-553.
2019
Li L, Chen H, Marin D, Xi Y, Miao Q, Lv J, Banerjee PProsad, Shaim H, Daher M, Basar R, et al. A novel immature natural killer cell subpopulation predicts relapse after cord blood transplantation. Blood Adv. 2019;3(23):4117-4130.
2018
Veltri L, Rezvani K, Oran B, Mehta R, Rondon G, Kebriaei P, Popat U, Nieto Y, Hosing C, Qazilbash M, et al. Allotransplants for patients 65 years or older with high-risk acute myeloid leukemia. Biol Blood Marrow Transplant. 2018.
2016
Zhao X, Tian X, Kajigaya S, Cantilena CR, Strickland S, Savani BN, Mohan S, Feng X, Keyvanfar K, Dunavin N, et al. Epigenetic landscape of the TERT promoter: a potential biomarker for high risk AML/MDS. Br J Haematol. 2016.
Ma Q, Garber HR, Lu S, He H, Tallis E, Ding X, Sergeeva A, Wood MS, Dotti G, Salvado B, et al. A novel TCR-like CAR with specificity for PR1/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cells. Cytotherapy. 2016.
Gaballa S, Ge I, Fakih REl, Brammer JE, Kongtim P, Tomuleasa C, Wang SA, Lee D, Petropoulos D, Cao K, et al. Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation. Cancer. 2016.
2015
Mehta RS, Rezvani K, Olson A, Oran B, Hosing C, Shah N, Parmar S, Armitage S, Shpall EJ. Novel Techniques for Ex Vivo Expansion of Cord Blood: Clinical Trials. Front Med (Lausanne). 2015;2:89.
Bayraktar UD, Milton DR, Guindani M, Rondon G, Chen J, Al-Atrash G, Rezvani K, Champlin R, Ciurea SO. Optimal Threshold and Time of Absolute Lymphocyte Count Assessment for Outcome Prediction after Bone Marrow Transplantation. Biol Blood Marrow Transplant. 2015.
2014
Ito S, A Barrett J, Dutra A, Pak E, Miner S, Keyvanfar K, Hensel NF, Rezvani K, Muranski P, Liu P, et al. Long term maintenance of myeloid leukemic stem cells cultured with unrelated human mesenchymal stromal cells. Stem Cell Res. 2014;14(1):95-104.

Pages